159142-09-3

Upstream product

• 157309-35-8 [2R-(2R*,3S,)]-N-t-Butyl-2-(3-amino-2-hydroxy-4-phenylbutyl) benzamide 
• 159142-07-1 (S)-2-<(tert-butoxycarbonyl)amino>-3-(2-quinolinylthio)propionic acid 
• 2637-37-8 Quinoline-2-thiol 
• 98541-64-1 N-(tert-butyloxycarbonyl)-D-serine β-lactone 

Downstream Products

• 161448-46-0 (S)-N-(1S,2R)-<3-<2-<<(1,1-dimethylethyl)amino>carbonyl>phenyl>-2-hydroxy-1-(phenylmethyl)propyl>-2-<(methylsulfonyl)amino>-3-(2-quinolinylthio)propanamide 
• 159142-11-7 (S)-N-(1S,2R)-<3-<2-<<(1,1-dimethylethyl)amino>carbonyl>phenyl>-2-hydroxy-1-(phenylmethyl)propyl>-2-(acetoxyamino)-3-(2-quinolinylthio)propanamide 
• 161448-45-9 2-{(2R,3S)-3-[(S)-2-Amino-3-(quinolin-2-ylsulfanyl)-propionylamino]-2-hydroxy-4-phenyl-butyl}-N-tert-butyl-benzamide 

Relevant academic research and scientific papers

Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands

Noncoded D-amino acids have been designed to replace the quinaldic amide- asparaginyl moiety (P2/P3 ligand) found in several potent human immunodeficiency virus (HIV) protease inhibitors such as LY289612. The substituted nitrogen, op